newsletter Conference News vaccines diversity vaccinology

Keypoint Newsletter: Health Equity in Vaccinology

In addition to covering emerging developments in vaccine science, design and technology, the Vaccinology During and After COVID-19 Keystone Symposium held in Atlanta on September 17-20, 2023, highlighted many aspects of health equity surrounding development and deployment of vaccines globally.  Dr. Barney Graham, of Morehouse School of Medicine, set the stage for these conversations with his Keynote Address, which covered the current state of the field, future directions, and challenges in global vaccine equity that need to be solved in the context of pandemic preparedness and response. Other health equity talks included meeting co-organizer Dr. Gangadeep Kang of the Bill & Melinda Gates Foundation, who shared insights on strategies for enhancing vaccine equity worldwide, before and after COVID-19.

These messages are of critical importance to the global research community, and public health worldwide, so we are releasing Drs. Graham's and Kang's presentations open access to inform broader audiences about these issues and inspire them to take action. Watch the videos below, complete with live audience Q&As on how to solve these important health equity issues!


See the full meeting program

 including talks by field leaders Drs. Robert Seder, Bali Pulendran, Rino Rappuoli & more!

2400x800_2024F6-KSVaccinology24

Other meeting highlights include sessions on:

  • Workshop on Equity in Vaccine Responses
  • Vaccine Platforms for COVID-19 and Beyond
  • Pan Pathogen Vaccines
  • T-Cell Based Vaccines
  • B Cell and Antibody Responses To Vaccination
  • Measuring and Predicting Immunity to Vaccination
  • Vaccinology in the Post-COVID Era

 

barney graham (1)-1

Keynote Address by Dr. Barney S. Graham- Morehouse School of Medicine 
Vaccine Equity and the Future of Global Health

 


kang

Dr. Gagandeep Kang- Bill & Melinda Gates Foundation
Enhancing Vaccine Equity Before and After COVID-19


Equity in Vaccine Responses Workshop

This workshop highlights biological differences in vaccine responses across different demographics of the population that should be considered when designing vaccines and developing dosing to ensure safety and efficacy across diverse populations. Speakers represent diverse global perspectives:

    • Fan Zhou (University of Bergen, Norway)
      Age Related Differences in Kinetics and Magnitude of SARS-CoV-2 and Endemic Human Coronavirus Reactive Antibody Responses After Vaccination and Infection
    • Lobke Hensen (University Medical Center Utrecht, Netherlands)
      T cell Immune Response Induced by Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Down Syndrome
    • Francesco Berlanda-Scorza† (GSK, Italy)
      A Strategic Model and Industry Collaboration for Sustainable Development of Vaccines against Neglected Diseases
    • Jerome Nyhalah Dinga (University of Buea, Cameroon)
      Combating the Loss in Childhood Immunization Gains in Rural Communities and Vaccination of Disabled Persons due to Covid-19: The Approach of Building Relationships and Harnessing Power in the Community
    • Ramya Madhavan (Christian Medical College, India)
      Characterization of Immune Responses to Two and Three Doses of the Adenoviral Vectored Vaccine ChAdOx1 nCov-19 and the Whole Virion Inactivated Vaccine BBV152 in a Mix-and-match Study in India




See more health equity content from Keystone Symposia! 


Donate to Our Diversity Initiatives to Support Health Equity Content!donate banner (1)

Return to the December 2023 Keypoint Newsletter

 

keypoint-logo-v2-544x180-1-300x112-1

 

Shannon Weiman
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.